Climb Bio Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Aoife Brennan

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Sep 23

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Feb 01

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

Jun 24

CEO

Aoife Brennan (48 yo)

no data

Görev süresi

Dr. Aoife M. Brennan, M.D. M.B., Ch B., BAO, MMSc, MRCPI, is CEO, President and Director at Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) Dr. Brennan serves as Director of Xilio Therapeutics...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Aoife Brennan	CEO, President & Director	no data	Veri yok	Veri yok
Brett Kaplan	COO & Principal Financial Officer	less than a year	Veri yok	Veri yok
Emily Pimblett	Chief Accounting Officer	1.8yrs	Veri yok	0.011% $ 24.4k
Jo Palmer-Phillips	Chief Development Officer	no data	Veri yok	Veri yok
Nishi Rampal	Senior Vice President of Clinical Development	less than a year	Veri yok	Veri yok

0.3yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: CLYM 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Aoife Brennan	CEO, President & Director	no data	Veri yok	Veri yok
Adam Rosenberg	Independent Director	4.1yrs	US$77.16k	0.26% $ 575.3k
Douglas Williams	Chair of Board	no data	Veri yok	Veri yok
Simon Tate	Independent Director	5.8yrs	US$22.52k	Veri yok
Andrew Levin	Director	no data	US$87.91k	0% $ 0
Stephen Thomas	Director	less than a year	Veri yok	0.15% $ 335.6k
Judith Dunn	Independent Director	3.8yrs	US$69.66k	0% $ 0

3.8yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CLYM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Climb Bio Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Climb Bio, Inc. Announces Board Changes

Eliem Therapeutics, Inc. Announces Executive Changes

Eliem Therapeutics, Inc. Announces Management Changes

Eliem Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Recent updates

Climb Bio, Inc. Announces Board Changes

Climb Bio, Inc. Present Additional Data from the Completed Pmn Trial and Share Clinical Data from A Single Patient with Minimal Change Disease (Mcd) Treated with Budoprutug

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Eliem Therapeutics, Inc. Announces Executive Changes

Eliem Therapeutics, Inc. (NasdaqGM:ELYM) completed the acquisition of Tenet Medicines, Inc. from RA Capital Management, L.P. and others.

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Eliem Therapeutics, Inc. announced that it has received $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

Eliem Therapeutics, Inc. Announces Management Changes

Eliem Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Eliem Therapeutics, Inc. announced that it expects to receive $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

New major risk - Share price stability

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

New minor risk - Shareholder dilution

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc

Eliem Therapeutics, Inc. Announces the Resignation of Leone Patterson from the Board of Directors

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Price target decreased to US$6.00

Eliem Therapeutics, Inc. Provides Update on Pipeline Progress

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics, Inc. Provides ETX-810 Program Update

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

Eliem Therapeutics, Inc. Announces Last Patient Completed Dosing in Phase 2A Study of ETX-810 in Patients with Lumbosacral Radicular Pain

Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from Russell 2500 Value Index

Eliem Therapeutics Reports Results from its Phase 2A Clinical Trial Investigating ETX-810 for the Treatment of Diabetic Peripheral Neuropathic Pain and Provided an Update on the Status of the ETX-155 Clinical Program in Epilepsy and Depression

Eliem Therapeutics, Inc., Annual General Meeting, May 19, 2022

Eliem Therapeutics, Inc. Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

High number of new directors

High number of new and inexperienced directors

Eliem Therapeutics, Inc. has completed an IPO in the amount of $80 million.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş